RT Journal Article
T1 Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome.
A1 Molina, Juan
A1 Navas, Ana
A1 Agüera, María-Luisa
A1 Rodelo-Haad, Cristian
A1 Alonso, Corona
A1 Rodríguez-Benot, Alberto
A1 Aljama, Pedro
A1 Solana, Rafael
K1 C1q-binding antibodies
K1 allograft-loss risk
K1 kidney allograft survival
K1 kidney transplantation
K1 preformed anti-HLA antibodies
K1 single antigen beads assay
AB The consolidation of single antigen beads (SAB-panIgG) assay in the detection of preformed anti-human leukocyte antigen (HLA) antibodies has improved transplantation success. However, its high sensitivity has limited the allograft allocation for sensitized patients, increasing their waiting time. A modification of the standard SAB-panIgG assay allows the detection of that subset of antibodies capable of binding C1q (SAB-C1q assay). However, the clinical usefulness of SAB-C1q assay for determining the unacceptable mismatches is under discussion. We retrospectively analyzed the impact of preformed donor-specific anti-HLA antibodies (DSA) according to the C1q-binding ability on allograft outcome, examining 389 single-kidney transplanted patients from deceased donors. Recipients with preformed C1q-binding DSA showed the lowest allograft survival up to 7 years (40.7%) compared to patients with preformed non-C1q-binding DSA (73.4%; p = 0.001) and without DSA (79.1%; p 
SN 1664-3224
YR 2017
FD 2017-10-31
LK https://hdl.handle.net/10668/25798
UL https://hdl.handle.net/10668/25798
LA en
DS RISalud
RD Apr 5, 2025